Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|February 23, 2021
How Machine Learning Can Help Improve the Operational Efficiency of Clinical Trials
Author(s)Oracle Health Services
*** Tuesday, February 23, 2021 at 1pm EST | 12pm CST | 10am PST *** Innovative machine learning techniques show great promise in helping life science companies identify and rectify systemic inefficiencies, much as they have in the automotive, financial services, insurance, and other industries. *** On demand available after final airing until Feb. 23, 2022 ***
Register free:
Event Overview:
The increasing complexity and spiraling costs of running clinical trials have forced life science organizations to renew their focus on improving operational efficiencies, particularly as the industry moves to embrace personalized medicine, with its lower per-patient revenue model.
There’s no silver bullet, of course. But innovative machine learning techniques show great promise in helping life science companies identify and rectify systemic inefficiencies, allowing them to learn and adapt.
In the automotive industry this innovative approach has propelled Tesla to become the leading car company based on market capitalization, dwarfing other automobile giants in just over 15 years.
Can machine learning bring about the same transformation to the pharmaceutical industry?
Key Learning Objectives:
In this webcast we will explore:
- What is required of life science companies to make machine learning a reality? Is it just technical expertise?
- What are the benefits and challenges of implementing machine learning?
- How will machine learning impact clinical staff, trial quality, risk management, patient engagement, costs, and site activations?
- How can machine learning help clinical researchers make more precise predictions and improve their daily activities now, as well as in the future?
Speakers: Artem Andrianov, CEO, Cyntegrity
Rohit Nambisan, President, Lokavant
Marcy Kravet, Head, Operational Design Center, EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany
A.J. Triano, EVP, Customer Experience Strategy, Syneos Health
Elvin Thalund, Director, Industry Strategy, Oracle Health Sciences
Sponsor: Oracle Health Sciences
Time and Date: Tuesday, February 23, 2021 at 1pm EST | 12pm CST | 10am PST
On demand available after final airing until Feb. 23, 2022
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5